Bivamelagon showed significant BMI reductions in hypothalamic obesity patients, prompting Rhythm Pharmaceuticals to seek FDA guidance for Phase 3 trials. Rhythm Pharmaceuticals, Inc. announced ...

Rhythm Pharmaceuticals, Inc. has announced that it received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide, a treatment aimed at acquired hypothalamic ...

Hypothalamic obesity (HyOb) is a type of obesity caused by damage to the brain’s hunger-regulating function. While there’s no cure, proper treatment can help improve your daily life and prevent ...

Hypothalamic obesity is a complex condition. Dietary changes won’t likely result in lasting weight loss, but there are other benefits for long-term health. The hypothalamus is a small but important ...